[{"orgOrder":0,"company":"Vasomune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"AV-001","moa":"Angiopoietin-1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Vasomune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vasomune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vasomune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"0B-002","moa":"CCR5","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Orion Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Scope International AG","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ Scope International AG","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biotechnology \/ Scope International AG"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"OB-002","moa":"CCR5 pathway","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orion Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Saptalis pharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Saptalis Pharm","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Saptalis Pharm"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"Growth hormone-releasing hormone receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theratechnologies \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Theratechnologies \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"APOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"APOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"APOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Bausch Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bausch Health \/ Undisclosed"},{"orgOrder":0,"company":"Akshaya Bio","sponsor":"Cytovance Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Akshaya Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akshaya Bio \/ Cytovance Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Akshaya Bio \/ Cytovance Biologics"},{"orgOrder":0,"company":"SaNOtize","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nitric Oxide","moa":"Soluble guanylate cyclase","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"SaNOtize","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gargle\/Mouthwash","sponsorNew":"SaNOtize \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SaNOtize \/ Undisclosed"},{"orgOrder":0,"company":"KGK Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Acacia Catechu","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"KGK Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Undisclosed"},{"orgOrder":0,"company":"Symvivo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Bactrl-Spike","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symvivo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ Undisclosed"},{"orgOrder":0,"company":"Symvivo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"bacTRL-Spike","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symvivo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ Undisclosed"},{"orgOrder":0,"company":"Symvivo","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"bacTRL-Spike Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symvivo \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ Undisclosed"},{"orgOrder":0,"company":"Symvivo","sponsor":"National Research Council Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"bacTRL-Spike Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Symvivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Symvivo \/ National Research Council Industrial Research Assistance Program","highestDevelopmentStatusID":"6","companyTruncated":"Symvivo \/ National Research Council Industrial Research Assistance Program"},{"orgOrder":0,"company":"Medicago","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"H1 VLP Influenza vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicago \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Medicago \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"Health Sciences Centre Winnipeg | Public Health Agency of Canada | Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"H7 VLP Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Medicago \/ Health Sciences Centre Winnipeg | Public Health Agency of Canada | Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Medicago \/ Health Sciences Centre Winnipeg | Public Health Agency of Canada | Syneos Health"},{"orgOrder":0,"company":"KGK Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Aloe Vera","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KGK Science \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ The Lind Partners","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ The Lind Partners"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Appili Therapeutics","sponsor":"Long Zone Holdings Inc.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"ATI-2307","moa":"Yeast Mitochondrial Respiratory Chain Complexes III-IV","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Appili Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Appili Therapeutics \/ Long Zone Holdings Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Appili Therapeutics \/ Long Zone Holdings Inc."}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
